Hepion Pharmaceuticals, Inc. (CTRVP) SEC Filings

Hepion Pharmaceuticals, Inc. (HEPA) director Gravitas Collective Corp. reported direct ownership of 25,000,000 shares of common stock as of October 6, 2026.

Hepion Pharmaceuticals, Inc. (HEPA) completed its acquisition of all issued and outstanding membership interests in Gravitas Life Sciences, LLC (GLS) from Gravitas Collective Corp., GLS’s sole member, on October 6, 2026. Consideration included $2,000,000 in cash and 25,000,000 common shares, with the shares stated as $2,250,000 divided by the Buyer Closing Stock Price. Issuance was capped at 19.99% of Hepion’s shares outstanding immediately following issuance, with any reduction settled in an equitable cash payment. Hepion also paid the seller $135,000. The shares are transfer-restricted until the earlier of six months after closing or registration for resale under an effective registration statement.

At closing, Hepion paid Canton Strategic Holdings $1,000,000 and GLS paid $125,000 from the cash consideration as prepayment of principal on the Canton Seller Note; Hepion became its sole maker, obligor and guarantor for remaining obligations. GLS develops GV104 for opioid-exposure prophylaxis and GV023, an oral infliximab formulation. GLS intends to file a GV104 NDA after CMC work; commercial-scale registration batches are intended to begin in 2027, and no dosing-window clinical study is in progress or scheduled. Disinterested directors approved the related-party transaction after directors Vincent LoPriore, Gary Stetz, Sireesh Appajosyula and Chase LoPriore disclosed interests and recused themselves; Hepion obtained a fairness opinion. Appajosyula was appointed CEO and Stetz CFO effective October 9, 2026.

Hepion Pharmaceuticals, Inc. director Danina Fisher reported purchasing 200,000 common shares at $0.05 per share and 200,000 warrants reported at $0.00 per warrant on September 29, 2026. After the transactions, she held 200,000 common shares and 200,000 warrants. The warrants have an exercise price of $0.06 per share and expire September 29, 2031. No Rule 10b5-1 plan is reported.

Hepion Pharmaceuticals, Inc. (HEPA) amended its Certificate of Incorporation to increase the authorized number of common shares to 750,000,000. The amendment became effective upon filing on October 1, 2026.

Hepion Pharmaceuticals, Inc. (HEPA) has a new Form 3 on file from KI Holdings, Ltd., which is reported as a ten percent owner. The filing reports existing positions rather than new trades.

KI Holdings holds warrants directly that are exercisable into 10,000,000 shares of Common Stock at an exercise price of $0.06 per share and expiring on August 3, 2031. It also reports indirect ownership of 10,000,000 shares of Common Stock, with a footnote stating KI Holdings is 100% owned by Kivowitz Investments, Inc., which is owned by Donald Kivowitz.

Hepion Pharmaceuticals, Inc. (HEPA) is the subject of an amended Schedule 13D reporting that KI Holdings Ltd., associated with investor Donald Kivowitz, has acquired 10,000,000 shares of common stock, representing 10.2% of the outstanding class, giving it sole voting and dispositive power over these shares.

The shares were purchased in a private placement under a Securities Purchase Agreement dated July 31, 2026, for an aggregate purchase price of $500,000, and were issued together with one warrant to purchase up to an additional 10,000,000 shares at an exercise price of $0.06 per share, immediately exercisable subject to a stated Beneficial Ownership Limitation. The filing states the securities were acquired for investment purposes and that the reporting persons may increase, decrease, or maintain their position depending on conditions.

Hepion Pharmaceuticals, Inc. (HEPA) received a Schedule 13G reporting that investor Kenneth Rickel beneficially owns 5,250,000 shares of its common stock, representing 5.7% of the outstanding shares. This total includes 2,000,000 shares issuable upon exercise of warrants.

As of August 10, 2026, Hepion had 90,219,317 shares of common stock outstanding, which is used as the denominator in calculating this ownership percentage. Rickel is reported to have sole voting power and sole dispositive power over all 5,250,000 shares and no shared voting or dispositive power.

Hepion Pharmaceuticals, Inc. (HEPA) insider Vincent S. LoPriore, Executive Chairman and director, reported the purchase of 12,500,000 warrants on September 3, 2026, indirectly through Gravitas Capital LP. These warrants are exercisable into 12,500,000 shares of common stock at $0.06 per share, expiring September 3, 2031, and become exercisable only upon stockholder approval of an increase in authorized common shares, bringing his indirectly held warrants to 22,500,000.

Hepion Pharmaceuticals, Inc. (HEPA) discloses that its board and majority stockholders, acting by written consent, have approved three major corporate actions: a potential reverse stock split, a large increase in authorized common shares, and a significant expansion of its 2023 Omnibus Equity Incentive Plan. The reverse split would reclassify issued and outstanding common stock at a ratio between 1-for-20 and 1-for-50, at the board’s discretion, any time up to the one-year anniversary of the August 31, 2026 record date, with fractional shares rounded up to the next whole share. The company’s certificate will also be amended to raise authorized common stock from 120,000,000 to 750,000,000 shares, leaving preferred stock authorization at 20,000,000 shares. The equity plan share reserve will increase from 8,000,000 to 18,000,000 shares, which Hepion states is about 18.3% of basic and 10.2% of fully diluted common shares as of the record date. These actions were approved by written consent of holders of a majority of the outstanding common stock and will become effective only after required notice periods and the filing of the respective charter amendments.